Literature DB >> 11688306

Community pharmacists' experience of over-the-counter medicine misuse in Scotland.

L MacFadyen1, D Eadie, T McGowan.   

Abstract

Over the last decade Britain has observed a trend towards the re-regulation of 'prescription only medicines' in favour of pharmacy status drugs. This move towards self-treatment to reduce pressures on general practitioner drug budgets and workloads has focused attention on the need for community pharmacists to extend their patient education and screening roles. In response to these changes, this study was conducted to explore: the type of over-the-counter (OTC) medicine being misused in Scotland; pharmacists' professional attitudes and management of OTC misuse; and the training and support needs of pharmacists. A postal questionnaire was designed. This was informed by an earlier stage of qualitative research and the available literature. It was then piloted and administered to all 110 pharmacies in the study area. A 79% response rate was achieved. The research found that OTC misuse, particularly of certain analgesics, sleeping prescriptions, products containing codeine or pseudoephedrine, caffeine, cough mixtures, and laxatives was common. The estimated mean number of patients suspected of misusing medicines in a typical week was 5.63. Pharmacies in urban areas were more likely than those in rural areas to report suspected misuse. The research identified a number of intervention strategies relating to: patient/pharmacist interaction; information provision; removal of products from the point of sale; sharing of information with other local pharmacists; and referral to other members of the primary care team. Pharmacists expressed a need for support in managing OTC misuse and in organising 'early warning systems' to share information locally.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11688306     DOI: 10.1177/146642400112100316

Source DB:  PubMed          Journal:  J R Soc Promot Health        ISSN: 1466-4240


  8 in total

1.  Association Between Parenting Stress and Functional Impairment Among Children Diagnosed with Neurodevelopmental Disorders.

Authors:  Yasser S Almogbel; Rohit Goyal; Sujit S Sansgiry
Journal:  Community Ment Health J       Date:  2017-02-08

Review 2.  A composite screening tool for medication reviews of outpatients: general issues with specific examples.

Authors:  Peter A G M De Smet; Wilma Denneboom; Cees Kramers; Richard Grol
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

3.  Evaluation of abuse and dependence on drugs used for self-medication: a pharmacoepidemiological pilot study based on community pharmacies in France.

Authors:  Ludivine Orriols; Julia Gaillard; Maryse Lapeyre-Mestre; Anne Roussin
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

4.  Codeine-induced hyperalgesia and allodynia: investigating the role of glial activation.

Authors:  J L Johnson; P E Rolan; M E Johnson; L Bobrovskaya; D B Williams; K Johnson; J Tuke; M R Hutchinson
Journal:  Transl Psychiatry       Date:  2014-11-11       Impact factor: 6.222

5.  Over-the-counter medications containing diphenhydramine and doxylamine used by older adults to improve sleep.

Authors:  Olufunmilola Abraham; Loren Schleiden; Steven M Albert
Journal:  Int J Clin Pharm       Date:  2017-05-02

6.  Virtual pharmacist interventions on abuse of over-the-counter medications during COVID-19 versus traditional pharmacist interventions.

Authors:  Nadia Al Mazrouei; Rana M Ibrahim; Ahmad Z Al Meslamani; Derar H Abdel-Qader; Osama Mohamed Ibrahim
Journal:  J Am Pharm Assoc (2003)       Date:  2021-02-12

7.  Over-the-counter medicine abuse - a review of the literature.

Authors:  Richard J Cooper
Journal:  J Subst Use       Date:  2011-10-03

8.  A comparative analysis of pharmacists' perspectives on codeine use and misuse - a three country survey.

Authors:  Tara Carney; John Wells; Charles D H Parry; Padraig McGuinness; Richard Harris; Marie Claire Van Hout
Journal:  Subst Abuse Treat Prev Policy       Date:  2018-03-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.